Alexis Borosy, EQRx CEO
#ASCO21: EQRx's cheaper EGFR drug busts Iressa in head-to-head test, and a US filing could be right down the road
With a slew of pricey oncology drugs dominating the market, disruptor EQRx has pledged to launch its own discounted competitors to bring the fight to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
